The rise of 3D bioprinting advancements in modeling neurodegenerative diseases

Abstract

Neurodegenerative diseases (NDs) are disorders that drastically alter the physiological functioning of neurons in the brain. These processes are often accompanied by abnormal protein aggregates that alter the physical and chemical properties of brain tissue and peripheral nerves. The causes of NDs are complex, involving genetic factors, neuroinflammation, oxidative stress, environmental influences, and lifestyle, while symptoms and progression vary significantly based on the mechanisms of cell death. Currently, no definitive treatment exists for NDs, as the underlying degenerative processes remain poorly understood. Existing therapies focus on symptom alleviation but are insufficient to halt or prevent disease progression. This highlights the urgent need for strategies that mimic the pathophysiology of NDs, facilitating deeper insights and the development of effective treatments. Conventional in vitro and in vivo models attempt to replicate NDs but often fail to capture the physiological complexity of nervous tissue and its interactions. In this context, 3D microfluidic bioprinting emerges as a transformative technology. By enabling precise deposition of cells and biomaterials, it allows the creation of in vitro models with a high degree of structural and functional complexity. These advancements provide a valuable platform for faithfully modeling NDs, bridging critical gaps in our understanding, and paving the way toward innovative therapeutic approaches.

Keywords

3D bioprinting / biofabrication / in vitro models / neurodegenerative diseases / tissue engineering

References

[1] Evangelisti C, Ramadan S, Orlacchio A, Panza E. Experimental cell models for investigating neurodegenerative diseases. Int J Mol Sci. 2024; 25(17):9747.

[2] Samanta S, Chakraborty S, Bagchi D. Pathogenesis of neurodegenerative diseases and the protective role of natural bioactive components. J Am Nutr Assoc. 2024; 43(1): 20-32.

[3] Cooper O, Hallett P, Isacson O. Upstream lipid and metabolic systems are potential causes of Alzheimer's disease, Parkinson's disease and dementias. FEBS J. 2024; 291(4): 632-645.

[4] Scarian E, Viola C, Dragoni F, et al. New insights into oxidative stress and inflammatory response in neurodegenerative diseases. Int J Mol Sci. 2024; 25(5):2698.

[5] Ricci C. Neurodegenerative disease: from molecular basis to therapy. Int J Mol Sci. 2024; 25(2):967.

[6] Wei M, Yang Z, Li S, Le W. Nanotherapeutic and stem cell therapeutic strategies in neurodegenerative diseases: a promising therapeutic approach. Int J Nanomedicine. 2023; 18: 611-626.

[7] Van Schependom J, D'haeseleer M. Advances in neurodegenerative diseases. J Clin Med. 2023; 12(5):1709.

[8] Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022; 23(3):1851.

[9] Rey F, Barzaghini B, Nardini A, et al. Advances in tissue engineering and innovative fabrication techniques for 3-D-structures: translational applications in neurodegenerative diseases. Cells. 2020; 9(7):1636.

[10] Pereira I, Lopez-Martinez MJ, Samitier J. Advances in current in vitro models on neurodegenerative diseases. Front Bioeng Biotechnol. 2023; 11(November): 1-20.

[11] Budday S, Ovaert TC, Holzapfel GA, Steinmann P, Kuhl E. Fifty Shades of Brain: A Review on the Mechanical Testing and Modeling of Brain Tissue. 27. Springer; 2020.

[12] Budday S, Steinmann P, Kuhl E. Physical biology of human brain development. Front Cell Neurosci. 2015; 9(July): 1-17.

[13] Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023; 8(1): 217.

[14] Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020; 17(1): 69.

[15] Akhtar A, Andleeb A, Waris TS, et al. Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Controlled Release. 2021; 330: 1152-1167.

[16] Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. In vitro models of neurodegenerative diseases. Front Cell Dev Biol. 2020; 8(May):328.

[17] Verghese JP, Terry A, de Natale ER, Politis M. Research evidence of the role of the glymphatic system and its potential pharmacological modulation in neurodegenerative diseases. J Clin Med. 2022; 11(23):6964.

[18] Cai Y, Zhang Y, Leng S, et al. The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: a vicious cycle. Neurobiol Dis. 2024; 192(January):106426.

[19] Buccellato FR, D'Anca M, Serpente M, Arighi A, Galimberti D. The role of glymphatic system in Alzheimer's and Parkinson's disease pathogenesis. Biomedicines. 2022; 10(9):2261.

[20] Spitz S, Ko E, Ertl P, Kamm RD. How organ-on-a-chip technology can assist in studying the role of the glymphatic system in neurodegenerative diseases. Int J Mol Sci. 2023; 24(3):2171.

[21] Urrestizala-Arenaza N, Cerchio S, Cavaliere F, Magliaro C. Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive. Front Cell Neurosci. 2024; 18(July):1419526.

[22] Iafrate L, Benedetti MC, Donsante S, et al. Modelling skeletal pain harnessing tissue engineering. In vitro models. 2022; 1(4-5): 289-307.

[23] Miny L, Maisonneuve BGC, Quadrio I, Honegger T. Modeling neurodegenerative diseases using in vitro compartmentalized microfluidic devices. Front Bioeng Biotechnol. 2022; 10(June): 1-17.

[24] de Vitis E, Stanzione A, Romano A, et al. The evolution of technology-driven in vitro models for neurodegenerative diseases. Adv Sci. 2024; 11(16):2304989.

[25] Centeno EGZ, Cimarosti H, Bithell A. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. Mol Neurodegener. 2018; 13(1): 27.

[26] Amartumur S, Nguyen H, Huynh T, et al. Neuropathogenesis-on-chips for neurodegenerative diseases. Nat Commun. 2024; 15(1): 2219.

[27] Akcay G, Luttge R. Microenvironments matter: advances in Brain-on-Chip. Biosensors. 2023; 13(5):551.

[28] Chiaradia I, Lancaster MA. Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo. Nature Neurosci. 2020; 23(12): 1496-1508.

[29] Tekin H, Simmons S, Cummings B, et al. Effects of 3D culturing conditions on the transcriptomic profile of stem-cell-derived neurons. Nat Biomed Eng. 2018; 2(7): 540-554.

[30] Li M, Sun H, Hou Z, Hao S, Jin L, Wang B. Engineering the physical microenvironment into neural organoids for neurogenesis and neurodevelopment. Small. 2024; 20(6): 1-20.

[31] Andrews MG, Kriegstein AR. Challenges of organoid research. Annu Rev Neurosci. 2022; 45: 23-39.

[32] Kelava I, Lancaster MA. Dishing out mini-brains: current progress and future prospects in brain organoid research. Dev Biol. 2016; 420(2): 199-209.

[33] Jiang W, Mei H, Zhao S. Applications of 3D bio-printing in tissue engineering and biomedicine. J Biomed Nanotechnol. 2021; 17(6): 989-1006.

[34] Cadena M, Ning L, King A, et al. 3D bioprinting of neural tissues. Adv Healthcare Mater. 2021; 10(15):2001600.

[35] Blaeser A, Duarte Campos DF, Puster U, Richtering W, Stevens MM, Fischer H. Controlling shear stress in 3D bioprinting is a key factor to balance printing resolution and stem cell integrity. Adv Healthcare Mater. 2016; 5(3): 326-333.

[36] Cidonio G, Glinka M, Dawson JI, Oreffo ROC. The cell in the ink: improving biofabrication by printing stem cells for skeletal regenerative medicine. Biomaterials. 2019; 209(April): 10-24.

[37] Qiu B, Bessler N, Figler K, et al. Bioprinting neural systems to model central nervous system diseases. Adv Funct Mater. 2020; 30(44):1910250.

[38] Budday S, Sommer G, Birkl C, et al. Mechanical characterization of human brain tissue. Acta Biomater. 2017; 48: 319-340.

[39] Feng Y, Murphy MC, Hojo E, Li F, Roberts N. Magnetic resonance elastography in the study of neurodegenerative diseases. J Magn Reson Imaging. 2024; 59(1): 82-96.

[40] Lozano R, Stevens L, Thompson BC, et al. 3D printing of layered brain-like structures using peptide modified gellan gum substrates. Biomaterials. 2015; 67: 264-273.

[41] Joung D, Lavoie NS, Guo SZ, Park SH, Parr AM, McAlpine MC. 3D printed neural regeneration devices. Adv Funct Mater. 2020; 30(1):1906237.

[42] Gu Q, Tomaskovic-Crook E, Wallace GG, Crook JM. 3D bioprinting human induced pluripotent stem cell constructs for in situ cell proliferation and successive multilineage differentiation. Adv Healthcare Mater. 2017; 6(17):1700175.

[43] Knowlton S, Cho Y, Li XJ, Khademhosseini A, Tasoglu S. Utilizing stem cells for three-dimensional neural tissue engineering. Biomater Sci. 2016; 4(5): 768-784.

[44] Hinton TJ, Jallerat Q, Palchesko RN, et al. Three-dimensional printing of complex biological structures by freeform reversible embedding of suspended hydrogels. Sci Adv. 2015; 1(9): 1-10.

[45] Nikolakopoulou P, Rauti R, Voulgaris D, Shlomy I, Maoz BM, Herland A. Recent progress in translational engineered in vitro models of the central nervous system. Brain. 2020; 143(11): 3181-3213.

[46] Szu JI, Binder DK. The role of astrocytic aquaporin-4 in synaptic plasticity and learning and memory. Front Integr Neurosci. 2016; 10(2016): 1-16.

[47] Silverglate B, Gao X, Lee HP, Maliha P, Grossberg GT. The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's disease. Expert Opin Ther Targets. 2023; 27(7): 523-530.

[48] D'Antoni C, Mautone L, Sanchini C, et al. Unlocking neural function with 3D in vitro models: a technical review of self-assembled, guided, and bioprinted brain organoids and their applications in the study of neurodevelopmental and neurodegenerative disorders. Int J Mol Sci. 2023; 24(13):10762.

[49] Zhu W, O'Brien C, O'Brien JR, Zhang LG. 3D nano/microfabrication techniques and nanobiomaterials for neural tissue regeneration. Nanomedicine. 2014; 9(6): 859-875.

[50] Knowlton S, Anand S, Shah T, Tasoglu S. Bioprinting for neural tissue engineering. Trends Neurosci. 2018; 41(1): 31-46.

[51] du Chatinier DN, Figler KP, Agrawal P, Liu W, Zhang YS. The potential of microfluidics-enhanced extrusion bioprinting. Biomicrofluidics. 2021; 15(4):041304.

[52] Serpe F, Casciola CM, Ruocco G, Cidonio G, Scognamiglio C. Microfluidic fiber spinning for 3D bioprinting: harnessing microchannels to build macrotissues. Int J Bioprint. 2024; 10(1):1404.

[53] Wang M, Li W, Mille LS, et al. Digital light processing based bioprinting with composable gradients. Adv Mater. 2022; 34(1): 1-13.

[54] Idaszek J, Costantini M, Karlsen TA, et al. 3D bioprinting of hydrogel constructs with cell and material gradients for the regeneration of full-thickness chondral defect using a microfluidic printing head. Biofabrication. 2019; 11(4):044101.

[55] Marcotulli M, Tirelli MC, Volpi M, et al. Microfluidic 3D printing of emulsion ink for engineering porous functionally graded materials. Adv. Mater. Technol. 2023; 8(5): 1-12.

[56] Mohammadi S, D'Alessandro S, Bini F, Marinozzi F, Cidonio G. Development of a microfluidic-assisted open-source 3D bioprinting system (MOS3S) for the engineering of hierarchical tissues. HardwareX. 2024; 18:e00527.

[57] D'Alessandro S, Mohammadi S, Iafrate L, et al. Hybrid 3D microfluidic bioprinting for the engineering of cancer models and tissue substitutes. Virtual Phys Prototyp. 2024; 19(1):e2419411.

[58] Serex L, Bertsch A, Renaud P. Microfluidics: a new layer of control for extrusion-based 3D printing. Micromachines. 2018; 9(2):86.

[59] Zhuang P, Sun AX, An J, Chua CK, Chew SY. 3D neural tissue models: from spheroids to bioprinting. Biomaterials. 2018; 154: 113-133.

[60] Samanipour R, Tahmooressi H, Rezaei Nejad H, Hirano M, Shin SR, Hoorfar M. A review on 3D printing functional brain model. Biomicrofluidics. 2022; 16(1):011501.

[61] Chen XB, Fazel Anvari-Yazdi A, Duan X, et al. Biomaterials/bioinks and extrusion bioprinting. Bioactive Materials. 2023; 28: 511-536.

[62] Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321(5893): 1218-1221.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.